Stock Track | Enovix Corporation Plunges 5.69% in Pre-Market on Weak Q1 Guidance, Revenue Miss, and Analyst Downgrade

Stock Track02-26

Enovix Corporation's stock experienced a significant pre-market plunge of 5.69% following the release of disappointing financial results and forward guidance.

The sell-off was driven by the company's weak Q1 2026 revenue forecast of $6.5 million to $7.5 million, which fell short of analyst estimates. Additionally, the company reported a 17.8% year-over-year decline in Q4 revenue to $7.99 million, missing expectations, and a substantial 218% surge in interest expenses for the full year 2025.

Further pressure came from analyst actions, including Canaccord Genuity cutting its price target on Enovix from $21 to $15, reflecting growing concerns about the company's near-term growth prospects and financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment